Filing Manager
CITADEL ADVISORS LLC
Reporting Manager
Kenneth Griffin
Symbol
ACRV
Shares outstanding
31,306,673 shares
Disclosed Ownership
1,721,867 shares
Ownership
5.5%
Form type
SCHEDULE 13G
Filing time
21 Nov 2025, 17:36:58 UTC
Date of event
14 Nov 2025
Previous filing
14 Nov 2025

Quoteable Key Fact

"CITADEL ADVISORS LLC disclosed 5.5% ownership in Acrivon Therapeutics, Inc. Common Stock, par value $0.001 per share (the "Shares") (ACRV) on 14 Nov 2025."

Quick Takeaways

  • CITADEL ADVISORS LLC filed SCHEDULE 13G for Acrivon Therapeutics, Inc. Common Stock, par value $0.001 per share (the "Shares") (ACRV).
  • Disclosed ownership: 5.5%.
  • Date of event: 14 Nov 2025.

What Changed

  • Previous schedule filing date: 14 Nov 2025.
  • Current filing was accepted on 21 Nov 2025, 17:36.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (7)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Citadel Advisors LLC 4.9% 1,541,326 0 1,541,326 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel Advisors Holdings LP 4.9% 1,541,326 0 1,541,326 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel GP LLC 4.9% 1,541,326 0 1,541,326 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel Securities LLC 0.6% 180,541 0 180,541 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel Securities Group LP 0.6% 180,541 0 180,541 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel Securities GP LLC 0.6% 180,541 0 180,541 /s/ Seth Levy Seth Levy, Authorized Signatory
Kenneth Griffin 5.5% 1,721,867 0 1,721,867 /s/ Seth Levy Seth Levy, attorney-in-fact*